Please assess the completion status of the following clinical trial:

Trial Title: Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients able to provide written informed consent~* Provision of informed consent prior to any study specific procedures~* Female and male patients aged 18-80 years~* Indication for CABG surgery~Exclusion Criteria:~* Cardiogenic shock, haemodynamic instability~* Need for urgent revascularization within 5 days from presentation~* Single vessel disease~* Two vessel disease with normal left ventricular function (\> 50%)~* Need for concomitant other cardiac surgery (e.g. valve replacement)~* Need for dual antiplatelet treatment for the patients undergoing CABG after acute coronary syndrome(ACS)~* Contraindication for aspirin and ticagrelor use(e.g. known allergy)~* History of bleeding diathesis within 3 months prior presentation~* History of significant GI bleed within 1 year prior presentation~* History of peptic ulcer without GI bleeding in past 3 years~* History of intracranial hemorrhage~* History of moderate to severe liver impairment~* Patient requires dialysis~* Patient with an increased risk of bradycardic events (as patients without a pacemaker who have sick sinus syndrome, 2nd or 3rd degree arteriolar-venular block or bradycardic-related syncope)~* Need vitamin K antagonist therapy after bypass surgery eg. persistent atrial fibrillation, mechanical valves~* Known, clinically important thrombocytopenia(i.e. \< 100\*109/L)~* Known, clinically important anaemia (i.e. \<100g/L)~* Participation in another investigational drug or device study in the last 30 days~* Pregnancy or lactation(for premenopausal women 2 methods of reliable contraception, one of which must barrier method, are required)~* Concomitant oral or intravenous therapy with strong cytochrome P450 3A4(CYP3A4) inhibitors, CYP3A4 substrates with narrow therapeutic indices, or strong CYP3A4 inducers which cannot be stopped for the course of the study (strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, over 1 litre daily of grapefruit juice. Substrates with narrow therapeutic index: cyclosporine, quinidine. Strong inducers: rifampin, phenytoin, carbamazepine. )~* Any other condition such as active cancer~* Life expectancy less than 12 months that may result in protocol non-compliance or a risk for being lost to follow up~* Indication for major surgery(e.g. cancer treatment, carotid surgery, cerebral surgery, major vascular surgery)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: ACTIVE_COMPARATOR): aspirin 100mg tablet by mouth daily for 12 months
- Ticagrelor plus Aspirin (Type: EXPERIMENTAL): ticagrelor 90mg tablet by mouth twice daily and aspirin 100mg tablet by mouth daily for 12 months
- Ticagrelor (Type: EXPERIMENTAL): ticagrelor 90mg tablet by mouth twice daily for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).